Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. - Wikidata - wikimedia - TriplyDB

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

http://www.wikidata.org/entity/Q33586020

about

MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells Clinical management of localized colon cancer with capecitabine Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Genetic risks and familial associations of small bowel carcinoma Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Implications of mismatch repair-deficient status on management of early stage colorectal cancer Treatment Individualization in Colorectal Cancer Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives Molecular phenotypes of colorectal cancer and potential clinical applications Deficient mismatch repair: Read all about it (Review)Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine Improving survival after endometrial cancer: the big picture Management of colorectal cancer Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review Tumor-specific microsatellite instability: do distinct mechanisms underlie the MSI-L and EMAST phenotypes?Different treatment strategies and molecular features between right-sided and left-sided colon cancers Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era HER2 activating mutations are targets for colorectal cancer treatment Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach PARP inhibitor treatment in ovarian and breast cancer MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy Gene Expression Variations in Microsatellite Stable and Unstable Colon Cancer Cells The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Literature review and practical aspects on the management of oxaliplatin-associated toxicity.Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer.BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2.Colorectal cancer: from prevention to personalized medicine.Prognostic and predictive significance of MSI in stages II/III colon cancer.Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers.Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

P2860

Q21133026-2222D8AD-DD5A-4CE3-B3A6-FCD6374DAA43 Q24611758-443D8A84-FA9D-4DE2-A4C2-2F7056F73AE7 Q26738655-7005EA23-CFA8-459A-90F7-F1987C7EA0ED Q26739607-0FD99964-DD6D-4EB8-94D4-87B2A838939B Q26744177-AA53DA84-C9AD-42D3-9636-AC99C52F179F Q26749012-A3A142C2-00CE-453B-BF4E-5CF385D4150D Q26751035-FE4331AC-B874-4851-94E5-840A65FF3FF6 Q26772272-11E75BD3-EA57-44C1-8DA6-35CFD9466305 Q26776215-34FBDE61-AF7B-4C69-ACAE-6C5A6D273D8F Q26779725-EE0DD50D-AC51-46A5-87F3-90CB8FABC238 Q26785725-687160F6-7E6D-4271-B48F-ECEBD96FCF77 Q26796491-37841581-1F47-4C57-86FC-2A2880182868 Q26800355-F0690586-2634-4A91-A9B6-CF1312901CEF Q26801354-9750275E-8965-42DF-A27B-2B33BC6EF18F Q26823550-E75E6DA3-34A1-4C7E-8BEF-B763C7B4D16C Q26863194-60D77F13-E1DC-4B2E-8666-76E483524CD6 Q26864622-D12E750D-D74F-4F76-B240-45D4EEA82F4B Q26865322-DE3B8622-7542-4426-B5C2-5138893C83F7 Q27693248-826A5E94-C894-470C-AA98-F9551EDDB3F2 Q27853193-726F0B4B-135D-42C2-B41A-84F2A7D8AF40 Q28070038-0DE97C07-4900-4E73-8DA4-2C5FB8CAE0B3 Q28080176-EF5BC0BB-9C26-4D22-B98A-610AF69DFB7A Q28647615-03323F5E-916B-4242-9E19-850D3A8895EB Q28741688-4BC7CCF1-9AD8-4F95-A6DC-F6BAD0E28083 Q28829013-300AC94A-A50A-4DE5-9542-F2C36FA070E2 Q29304665-0613D65C-E8ED-4BEB-A912-67B8600BCBD8 Q30234889-048E93F9-572F-4CC0-B9B3-E1430789F0FE Q31012680-48C69C6B-12F0-4FB8-937F-77054FBD563E Q33398649-6C79F809-69A0-434C-A75C-5901383880C4 Q33576805-14DA910D-89FD-4EB3-8CB8-1F541D64083D Q33599071-81DF32D4-8505-48BB-BCE3-567B893CDE95 Q33615076-2E777A90-FF33-4BEC-8A02-8D1B4C7F94E4 Q33682949-891FFBD6-8CDE-4973-8FDB-3D19AAA25093 Q33726141-E5AE2B00-2CA6-4888-8515-0B51F3288E67 Q33735234-2EF01DC2-D785-461E-B8E1-4C337D0D3D41 Q33735239-69CE349A-63D1-4C2E-A359-3084B9E48DE8 Q33765195-96FB485C-AD04-408B-B0FE-2F406ED1022B Q33775296-9030CA88-9E5B-4806-A259-A51FB0EC0821 Q33798773-AF572ED2-473D-4B58-AF5A-8DBC1A2B4A9E Q33813216-C78DAE1A-F8D3-404F-A74C-6C58F1E3DCEA

P2860

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

http://www.wikidata.org/entity/Q33586020

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@ast

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@en

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@nl

type

label

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@ast

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@en

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@nl

prefLabel

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@ast

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@en

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@nl

P1433

Q33586020-F5BE524F-EB6D-4019-B256-B5B80BCB449B

P1476

Q33586020-32397050-AB4A-4A99-8F2E-0886FE91479D

P2093

Q33586020-0D073A8B-FBE4-457C-9AFE-C70857843BA7

Q33586020-27514AAF-AA1F-4DA7-9B31-286181817AF8

Q33586020-3A167CBF-A56B-457A-90C1-02058EF9EAEA

Q33586020-5866C96B-62B4-4616-9A5A-08A9E37F9137

Q33586020-5A035673-F826-4885-A9E0-577DBBFAD7E2

Q33586020-5A4A587C-6EEB-47B1-B295-101222978146

Q33586020-610D80A7-5BDE-427B-9714-1392291208CD

Q33586020-94C08AD7-56CD-4DA2-86BF-FC63EC85667E

Q33586020-BF778BD4-5EDB-40FE-9233-E95C76029486

Q33586020-C34ACE63-AC90-492E-AC33-5CF393590935

P2860

Q33586020-052A5767-D5EB-4FE7-8C7F-700756C8C3E4

Q33586020-0676D54A-B74E-4CCD-9C6D-531AF452261E

Q33586020-069688AA-2375-45C0-AF78-13BCE7C54BEF

Q33586020-0704AD07-53B4-4D08-8107-1F3EC4106FE2

Q33586020-09088BB0-155C-45E1-B10A-1D83DB43ED53

Q33586020-15EEC021-D6A2-4B59-B3EB-A9D3A6381982

Q33586020-1BC62750-51F9-4515-BD8D-B50857EA4870

Q33586020-22EF5D1F-3258-4D55-9E5C-1AC01E4C0239

Q33586020-2626827B-6673-4D67-8BB7-4AE81A9267DB

Q33586020-2930517B-2663-4C77-848D-9EDC21216806

P304

Q33586020-EB5DCE41-A955-401E-8A0E-1E3A2C29F5C1

P31

Q33586020-E9D7CC57-D44F-4887-81D7-76A6CBFA87F8

P356

Q33586020-D5DF73CF-A68C-434C-B91A-4BC7176C4FAF

P407

Q33586020-B2800D03-3147-4382-9FBD-6D63BFC1411D

P433

Q33586020-EA4C59DD-6DD3-4401-AC7E-1D661E7399C3

P478

Q33586020-85D70283-AE30-4791-AB3F-6DD125B793C0

P50

Q33586020-1F68F98B-CBB1-4E58-82C6-C8A6B38B9B5D

Q33586020-6D7E48D6-3B92-412E-8E9E-07D43C7A5478

Q33586020-A2A88E4B-E7BB-4D70-948F-2F1CCE5976E7

P577

Q33586020-8E50AA7F-9813-4203-B5B6-4DFAD15C976D

P698

Q33586020-F3AEAB05-90B5-4E07-BD31-F36E83A57A75

P932

Q33586020-E0AD98F2-C074-4998-AA8C-7E9784496A7E

P356

JCO.2009.27.1825

P1433

Journal of Clinical Oncology

P1476

Defective mismatch repair as a ...... uvant therapy in colon cancer.

@en

P2093

Alberto Zaniboni

http://www.w3.org/2001/XMLSchema#string

Amy J French

http://www.w3.org/2001/XMLSchema#string

Axel Grothey

http://www.w3.org/2001/XMLSchema#string

Brian Kabat

http://www.w3.org/2001/XMLSchema#string

Christine Ribic

http://www.w3.org/2001/XMLSchema#string

Frank Sinicrope

http://www.w3.org/2001/XMLSchema#string

Genevieve Monges

http://www.w3.org/2001/XMLSchema#string

Jean-Francois Seitz

http://www.w3.org/2001/XMLSchema#string

Malcolm Moore

http://www.w3.org/2001/XMLSchema#string

Nathan R Foster

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Systematic review of microsatellite instability and colorectal cancer prognosis

Microsatellite instability in cancer of the proximal colon

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.

The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.

Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

P304

3219-3226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.1825

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Labianca

Daniel J. Sargent

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20498393

http://www.w3.org/2001/XMLSchema#string

P932

2903323

http://www.w3.org/2001/XMLSchema#string